Document Detail

Mycobacterium interface keratitis after laser in situ keratomileusis.
MedLine Citation:
PMID:  11733259     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To report the clinical course, management, and outcome of infectious interface keratitis caused by mycobacterium species after laser in situ keratomileusis (LASIK). DESIGN: A small noncomparative interventional case series. PARTICIPANTS: Five eyes in four patients who underwent LASIK in different locations around the world and had culture-positive mycobacterium keratitis develop. INTERVENTION: The LASIK flap was lifted or amputated, samples were submitted for Ziehl-Neelsen acid-fast stain and Lowenstein-Jensen's agar cultures for diagnosis; topical treatment with fortified clarithromycin and amikacin was administered until clinical resolution. MAIN OUTCOME MEASURES: Time periods from onset to diagnosis and from diagnosis to clinical resolution, and the final visual acuity. RESULTS: Onset of symptoms of infection occurred after a mean of 20 days (range, 11 days-6 weeks) after LASIK or an enhancement procedure. Definitive diagnosis was obtained after a mean period of 4.5 weeks (range, 12 days-8 weeks) from onset. Keratitis resolved within 8.4 weeks (range, 1-18 weeks) of treatment with fortified clarithromycin and amikacin. Corticosteroids were found to worsen and prolong the course of disease. In four of five eyes the LASIK flap was amputated. CONCLUSIONS: Mycobacterial keratitis is a potentially vision-threatening complication after LASIK, characterized by a long latent period, delayed diagnosis, and a protracted course even under intensive specific antibiotic therapy. Inclusion of specific culture media and staining protocols for mycobacteria, along with aggressive treatment on diagnosis, including lifting or amputating the LASIK flap, culturing, topical fortified clarithromycin and amikacin, while avoiding corticosteroids, may significantly improve resolution of the infection and potentially improve the visual outcome.
A Solomon; C L Karp; D Miller; S R Dubovy; A J Huang; W W Culbertson
Related Documents :
16805119 - Effect of prophylactic and therapeutic mitomycin c on corneal apoptosis, cellular proli...
11864879 - Phototherapeutic keratectomy re-treatment for recurrent corneal erosion syndrome.
16018819 - Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in ph...
18216569 - Therapeutic keratoplasty for corneal perforation: clinical results and complications.
9437309 - The madurai intraocular lens study. ii: clinical outcomes.
20508509 - Bilateral comparison of conventional epithelial laser in situ keratomileusis and lamell...
2794919 - Retrospective analysis of 97 patients with infective endocarditis seen over the past 8 ...
20516309 - Brace wear control of curve progression in adolescent idiopathic scoliosis.
18043109 - Inflammation-based prognostic score is a novel predictor of postoperative outcome in pa...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Ophthalmology     Volume:  108     ISSN:  0161-6420     ISO Abbreviation:  Ophthalmology     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-12-04     Completed Date:  2001-12-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2201-8     Citation Subset:  IM    
Department of Ophthalmology, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amikacin / therapeutic use
Clarithromycin / therapeutic use
Cornea / microbiology
Drug Therapy, Combination / therapeutic use
Eye Infections, Bacterial / diagnosis,  drug therapy,  etiology*
Keratitis / diagnosis,  drug therapy,  etiology*
Keratomileusis, Laser In Situ / adverse effects*
Middle Aged
Mycobacterium Infections, Atypical / diagnosis,  drug therapy,  etiology*
Mycobacterium chelonae / isolation & purification
Time Factors
Reg. No./Substance:
37517-28-5/Amikacin; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Otago glaucoma surgery outcome study: long-term follow-up of cases of primary glaucoma with addition...
Next Document:  Corneal irregular astigmatism and contrast sensitivity after photorefractive keratectomy.